The aerosolised vaccine will use Aerogen Solo vibrating mesh nebuliser for drug delivery. Credit: Business Wire.

CanSinoBIO has signed a development and commercial supply collaboration with Ireland based company Aerogen for the inhaled recombinant Covid-19 vaccine, Convidecia.

Under the partnership, the aerosolised vaccine will use Aerogen’s vibrating mesh aerosol technology for delivery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The companies have not divulged the financial details of the collaboration.

Convidecia is intended to be directly inhaled through a cup dispenser into the airway of the individual.

This route imitates the SARS-CoV-2 virus’ natural infection pathway and could offer further benefits by inducing mucosal immunity.

According to interim data from CanSinoBIO’s Phase III clinical trials, the vaccine showed a 95.47% efficacy in severe Covid-19 prevention 14 days following administration of a single dose.

As vaccination through the inhaled aerosol route needs a significantly reduced vaccine volume, it offers the capability to inoculate a greater number of individuals in a cost-efficient manner than injectable vaccines.

Aerogen CEO and founder John Power said: “The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination.

“The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”

CanSinoBio is planning a commercial authorisation application in China.

The company is preparing further clinical trials for other countries.

CanSinoBIO chairman and CEO Dr Xuefeng YU said: “Our partnership with Aerogen started in 2013 and for almost a decade, we’ve been advancing the possibility of aerosol drug delivery.

“It is demonstrated that the aerosolised vaccine can stimulate mucosal immunity and significantly reduce the risk of transmission, which could be a solution to rapidly build mass immune protection and accelerate the end of the pandemic.”

In April, the company announced plans to start trials of its inhaled Covid-19 vaccine.